Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis

Clin Exp Dermatol. 2019 Oct;44(7):e243-e244. doi: 10.1111/ced.14000. Epub 2019 May 20.

Authors

L Sacchelli¹, A Patrizi¹, C Loi¹, F Bardazzi¹

Affiliation

¹ Department of Specialized, Clinical and Experimental Medicine, Division of Dermatology, University of Bologna, Bologna, Italy.

PMID: 31055844
DOI: 10.1111/ced.14000

No abstract available

Publication types

Letter

MeSH terms

Adult
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use*
Combined Modality Therapy
Female
Humans
Male
Middle Aged
Psoriasis / drug therapy*
Psoriasis / pathology
Severity of Illness Index
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use
Treatment Outcome

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal, Humanized
Thalidomide
secukinumab
apremilast